| 摘要 |
<p>Use of marker sequences for the diagnosis of systemic lupus erythematosus, where at least one marker sequence of a cDNA comprising sequences of 1-716 and/or sequences of 1a-716a or their coded proteins or their partial sequences or fragments is determined from a patient to be examined, and the sequences are not defined, is claimed. Independent claims are included for: (1) diagnosis of systemic lupus erythematosus, comprising applying the marker sequence on a solid support, contacting the marker sequence with a body fluid or tissue extract of a patient, and carrying out the detection of an interaction of the body fluid or tissue extract containing the marker sequences; (2) stratifying, preferably for risk stratification or therapy control of a patient with systemic lupus erythematosus, comprising determining the marker sequence from the patient to be examined; (3) arrangement of the marker sequences; (4) assay, protein biochip comprising the arrangement, in which the marker sequences are applied on a solid support; (5) diagnostic agents for the diagnosis of systemic lupus erythematosus, comprising the sequences as above per se; and (6) target for the treatment and therapy of systemic lupus erythematosus, comprising the sequences as above per se. ACTIVITY : Antiinflammatory; Dermatological; Immunosuppressive. MECHANISM OF ACTION : None given.</p> |
